Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

Study Summary

The aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated colorectal cancer (CRC) receiving sotorasib 240 mg once daily (QD) and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib), and sotorasib 960 mg QD and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib).

Conditions

Colorectal Cancer (CRC)

Interventions / Drugs

Sotorasib Panitumumab Trifluridine and Tipiracil Regorafenib

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment160 participants

Primary Completion—

Lead SponsorAmgen

Data Retrieved2026-04-13 18:29:34.157791+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.